Technical articles
Two long-form articles cover VHH structural and development advantages, plus the clinical progress of approved and investigational nanobody drugs — available in Chinese and English.
SanjingBio's nanobody technology series is now live. The first two long-form bilingual articles focus on VHH structure and development advantages, and on the clinical progress of approved and investigational nanobody medicines.
The series covers VHH molecular structure, stability and engineering characteristics before extending into clinical applications and development pipelines, connecting technical principles with translational progress.
Core instruments now number 13. The 300 kV cryo-EM will be used for epitope analysis and complex-structure confirmation, supporting antigen design and antibody screening on membrane proteins and other hard targets.
Jul 21, 2026
Deliveries span mammalian, insect, yeast, E. coli and cell-free systems, with hard targets such as multi-pass membrane proteins taking a growing share.
Jun 12, 2026
New SKUs concentrate on solid tumours and autoimmune disease; every in-stock item ships immediately with purity data and ELISA binding validation.
May 8, 2026
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
